文献速递贫血与红细胞疾病血栓与止血

加利福尼亚州镰状细胞病女性的妊娠结局

Pregnancy outcomes in women with sickle cell disease in California.
PubMed 文献 · Am J Hematol · 2023-01-04

基于加利福尼亚州1991-2019年数据,按年龄、保险状态和 distressed community index 评分校正后,比较黑人镰状细胞病(SCD)与非SCD孕妇的妊娠结局。SCD组死产和住院孕产妇死亡率更高,脓毒症、静脉血栓栓塞和产后出血的比值比显著升高,校正社会人口学因素后差异仍存在。作者提出需进一步研究早期生殖健康教育、妊娠期继续SCD修饰治疗及多学科围产期照护可及性能否降低发病率。

要点

  • 黑人SCD孕妇较非SCD孕妇更年轻分娩、更多使用政府保险、更多居住于 at-risk 或 distressed 社区。
  • SCD组死产为每1000例出生26.8例(95%CI 17.5-36.1),非SCD组为12.4例(95%CI 12.1-12.7)。
  • SCD组住院孕产妇死亡为每10万活产344.5例(95%CI 337.6-682.2),非SCD组为6.1例(95%CI 2.3-8.4)。

核心结论

  • 校正社会人口学因素后,黑人SCD女性妊娠结局仍显著差于非SCD黑人女性。
  • 作者提出需进一步研究早期生殖健康教育、妊娠期继续SCD修饰治疗及增加多学科围产期照护可及性能否降低SCD孕妇发病率。

研究设计与样本

  • 使用加利福尼亚州 Department of Health Care Access and Information 数据(1991-2019年),估算黑人SCD与非SCD女性妊娠结局的累积发生率,并按年龄、保险状态和 Distressed Community Index 评分校正。

主要发现

  • 黑人SCD孕妇较非SCD孕妇更年轻分娩、更多使用政府保险、更多居住于 at-risk 或 distressed 社区。
  • SCD组死产为每1000例出生26.8例(95%CI 17.5-36.1),非SCD组为12.4例(95%CI 12.1-12.7)。
  • SCD组住院孕产妇死亡为每10万活产344.5例(95%CI 337.6-682.2),非SCD组为6.1例(95%CI 2.3-8.4)。
  • 多变量logistic回归显示,黑人SCD孕妇脓毒症OR 14.89(95%CI 10.81-20.52)、静脉血栓栓塞OR 13.60(95%CI 9.16-20.20)、产后出血OR 2.25(95%CI 1.79-2.82),峰值发病分别见于第二孕期、第三孕期和产后六周。

关键数值与推荐

  • 死产:SCD组每1000例出生26.8例(95%CI 17.5-36.1)vs 非SCD组12.4例(95%CI 12.1-12.7)。
  • 住院孕产妇死亡:SCD组每10万活产344.5例(95%CI 337.6-682.2)vs 非SCD组6.1例(95%CI 2.3-8.4)。
  • 脓毒症OR 14.89(95%CI 10.81-20.52),静脉血栓栓塞OR 13.60(95%CI 9.16-20.20),产后出血OR 2.25(95%CI 1.79-2.82)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adverse pregnancy outcomes occur frequently in women with sickle cell disease (SCD) across the globe. In the United States, Black women experience disproportionately worse maternal health outcomes than all other racial groups. To better understand how social determinants of health impact SCD maternal morbidity, we used California's Department of Health Care Access and Information data (1991-2019) to estimate the cumulative incidence of pregnancy outcomes in Black women with and without SCD-adjusted for age, insurance status, and Distressed Community Index (DCI) scores. Black pregnant women with SCD were more likely to deliver at a younger age, use government insurance, and live in at-risk or distressed neighborhoods, compared to those without SCD. They also experienced higher stillbirths (26.8, 95% confidence interval [CI]: 17.5-36.1 vs. 12.4 [CI: 12.1-12.7], per 1000 births) and inpatient maternal mortality (344.5 [CI: 337.6-682.2] vs. 6.1 [CI: 2.3-8.4], per 100 000 live births). Multivariate logistic regression models showed Black pregnant women with SCD had significantly higher odds ratios (OR) for sepsis (OR 14.89, CI: 10.81, 20.52), venous thromboembolism (OR 13.60, CI: 9.16, 20.20), and postpartum hemorrhage (OR 2.25, CI 1.79-2.82), with peak onset in the second trimester, third trimester, and six weeks postpartum, respectively. Despite adjusting for sociodemographic factors, Black women with SCD still experienced significantly worse pregnancy outcomes than those without SCD. We need additional studies to determine if early introduction to reproductive health education, continuation of SCD-modifying therapies during pregnancy, and increasing access to multidisciplinary perinatal care can reduce morbidity in pregnant women with SCD.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Adesina OO, Brunson A, Fisch SC, et al. Pregnancy outcomes in women with sickle cell disease in California. Am J Hematol. 2023. PMID: 36594168. doi:10.1002/ajh.26818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。